SK pens $315M pact with fellow South Korean company for Parkinson’s prospect

SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer.